Pakistan's macroeconomic indicators have deteriorated significantly since first-quater 2010. The rupee has depreciated against the US dollar, gross domestic product (GDP) projections have been downgraded, inflation has increased and fiscal expenditure has contracted, notes Business Monitor International's Pakistan Pharmaceuticals and Healthcare Report. Therefore, Pakistan's $1.61 billion pharmaceutical market is now expected to post a five-year compound annual growth rate of 8.95%, down from 9.39% forecast in the previous quarter.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze